- Coordinator
- Martin-Luther-Universitat Halle-Wittenberg, Germany
- Runs
- 1 April 2024 to 31 March 2029
- Status
- Running
- EU funding
- €8.0m
- Total cost
- €8.0m
- Partners
- 23 organisations in 8 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101136502
What the project is doing
In the project's own words, from its summary on CORDIS.
Measurable residual disease (MRD) detected by multiparameter flow cytometry (MFC) has strong prognostic value in patients with the most frequent acute and chronic leukemias, acute myeloid (AML) and chronic lymphocytic leukemia (CLL), but it has not yet been confirmed as a treatment-guiding biomarker. The RESOLVE Consortium will leverage numerous existing expert networks and patient advocacy partnerships to establish the predictive value of MRD in AML/CLL patients, with the expectation that this affordable, minimally-invasive biomarker can be imminently used to guide the intensity of consolidation therapy, improve quality of life (QoL), and reduce costs.
This will be achieved through 1) development of a real-world patient registry and data platform
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Martin-Luther-Universitat Halle-Wittenberg | Halle | Germany | Coordinator |
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Participant |
| Deutsches Krebsforschungszentrum Heidelberg | Heidelberg | Germany | Participant |
| European Research Initiative on Cll eV | Koln | Germany | Participant |
| Medizinische Hochschule Hannover | Hannover | Germany | Participant |
| Osho, Ostdeutsche Studiengruppe Hamatologie Und Onkologie E.v. | Leipzig | Germany | Participant |
| Stiftung Eln Foundation | Weinheim | Germany | Participant |
| Technische Universitaet Dresden | Dresden | Germany | Participant |
| Universitaet Ulm | Ulm | Germany | Participant |
| Elliniki Aimatologiki Etaireia | Athens | Greece | Participant |
| Fundacion Instituto De Estudios De Ciencias De La Salud De Castilla Y Leon | Soria | Spain | Participant |
| French Innovative Leukemia Organization | Tours | France | Participant |
| Shaare Zedek Medical Center | Jerusalem | Israel | Participant |
| Azienda Usl Della Romagna | Ravenna | Italy | Third party |
| Fondazione G.i.m.em.a. - Franco Mandelli Onlus | Roma | Italy | Participant |
| Istituto Di Ricerche Farmacologiche Mario Negri | Milano | Italy | Participant |
| Istituto Romagnolo per Lo Studio Dei Tumori Dino Amadori - Irst SRL | Meldola | Italy | Participant |
| Universita Commerciale Luigi Bocconi | Milano | Italy | Participant |
| Universita Degli Studi Di Roma Tor Vergata | Roma | Italy | Participant |
| Flowview Diagnostics BV | Heerenveen | Netherlands | Participant |
| Ortec Optimization Technology BV | Zoetermeer | Netherlands | Participant |
| Stichting Amsterdam Umc | Amsterdam | Netherlands | Participant |
| Stowarzyszenie Polskiej Grupy D/s Leczenia Bialaczek U Doroslych Palg/polish Adult Leukemia Group | Gliwice | Poland | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI